If you get ‘the ick' often, you probably possess this negative personality trait — study says
If you're someone who regularly gets the ick from someone you're dating — you might be a narcissist.
The term that refers to the feeling of disgust from something a romantic partner does, says or even wears has gone viral on social media in recent years.
And according to a study published in Personality and Individual Differences, those who experience this feeling often might possess personality traits that indicate narcissism.
For the study, researchers analyzed 74 men and 51 women, ranging in age from 24 to 72. They asked the participants if they knew what getting the ick meant and if they've ever experienced it.
The study then measured the 'likelihood of experiencing the ick in response to specific behaviors, completed personality assessments and answered questions about their dating experiences,' according to Psy Post.
Regarding the personality assessments participants took part in, those who showed narcsictic behavior were more likely to negatively react to a person's imperfections — especially if it contracticed what they want in a potential romantic partner.
The results of the study also indicated that women experience the ick more often compared to men — which isn't surprising considering adult females are 'more sensitive to grossness than males,' according to a scientific dive by NatGeo.
'Anything we are averse to, that we want to avoid, or that we shrink back from — including the ick — is controlled by this area of the brain [called the habenula],' Dr. Kyra Bobinet, a California behavioral neuroscientist and author of 'Unstoppable Brain,' told Fox News Digital.
'This area of your brain is scouting for anything that's not going to work out for you,' she said. 'It has a negativity bias.'
As a result, people will either immediately (26 %) or eventually (42%) end things with someone over an ick that turned them off, according to the Personality and Individual Differences study.
While many daters are quick to get rid of a potential suitor because of their quirks, study author Eliana Saunders said that people should take icks with a grain of salt and maybe think twice before completley writing off someone.
'While this feeling of disgust could be a valid marker of mate incompatibility, it could also be a symptom of high sensitivity to disgust, narcissism, other-oriented perfectionism, etc.'
'Before dumping a partner because their feet dangle when they sit in a chair, we should think critically about why we're feeling 'icked' out. Ask yourself: Is this something I truly can't deal with, or am I being overly critical? Is this 'ick' their fault, or is it mine?''
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
AbbVie to buy Capstan Therapeutics for up to $2.1 billion
(Reuters) -AbbVie said on Monday it will acquire Capstan Therapeutics in a deal worth up to $2.1 billion, adding experimental treatments for autoimmune diseases to its portfolio.
Yahoo
an hour ago
- Yahoo
5 Must-Read Analyst Questions From Astrana Health's Q1 Earnings Call
Astrana Health's first quarter results for 2025 were met with a negative market reaction, with revenue growth driven by its Care Partners segment and progress in full-risk contracts. However, management acknowledged that the quarter's performance was tempered by lower-than-expected revenue and compressed operating margins. CEO Brandon Sim pointed to the flu season and higher emergency room and lab utilization in Medicaid as factors impacting costs, while also highlighting ongoing investments in technology and integration. Sim stated, 'Margins were moderated by planned ongoing investments in growth integration technology, as well as by revenue growth in areas with lower near-term margin profiles.' Is now the time to buy ASTH? Find out in our full research report (it's free). Revenue: $620.4 million vs analyst estimates of $636.2 million (53.4% year-on-year growth, 2.5% miss) Adjusted EPS: $0.34 vs analyst estimates of $0.33 (in line) Adjusted EBITDA: $36.39 million vs analyst estimates of $35.7 million (5.9% margin, 1.9% beat) The company reconfirmed its revenue guidance for the full year of $2.6 billion at the midpoint EBITDA guidance for the full year is $180 million at the midpoint, below analyst estimates of $181.2 million Operating Margin: 3.3%, down from 7.5% in the same quarter last year Market Capitalization: $1.23 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Ryan Daniels (William Blair) asked about remaining milestones for CHS integration. CEO Brandon Sim explained integration is complete, but further implementation of the care model should drive margin improvements over time. Michael Ha (Baird) pressed on the seasonality and drivers behind the lighter revenue outlook for next quarter. Sim attributed this to Medicaid volatility and full-risk conversions being weighted toward the second half of the year. Jack Slevin (Jefferies) questioned Astrana's confidence in leveraging favorable Medicare Advantage rates. Sim responded that while the rate update was anticipated, its exact financial impact will become clearer as more details emerge. Jailendra Singh (Truist Securities) asked about profitability in the ACO REACH program and the impact of recent risk adjustment changes. Sim shared that the company absorbed a modest drag from retroactive adjustments, offset by other risk-management strategies. Brooks O'Neil (Lake Street Capital Markets) probed on organizational stress from rapid growth and integration. Sim acknowledged the challenges of scaling rapidly, emphasizing ongoing focus on integration and cultural cohesion. In the upcoming quarters, the StockStory team will be monitoring (1) the pace and effectiveness of integrating Prospect Health and realizing promised synergies, (2) the continued conversion of members to full-risk contracts and resulting margin trends, and (3) the outcome of Medicaid contract renewals and regulatory developments in key states. Progress in leadership-driven data and technology initiatives will also be a key signpost for sustainable growth. Astrana Health currently trades at $24.73, down from $33.40 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it's free). The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.


Washington Post
an hour ago
- Washington Post
EPA employees put names to 'declaration of dissent' over agency moves under Trump
A group of Environmental Protection Agency employees on Monday published a declaration of dissent from the agency's policies under the Trump administration, saying they 'undermine the EPA mission of protecting human health and the environment.' More than 170 EPA employees put their names to the document, with about 100 more signing anonymously out of fear of retaliation, according to Jeremy Berg, a former editor-in-chief of Science magazine who is not an EPA employee but was among non-EPA scientists or academics to also sign. The latter figure includes over 70 Nobel laureates.